Venus Remedies receives marketing authorisation from Azerbaijan for anticoagulant, enoxaparin

Venus Remedies Limited, a leading fixed-dosage injectable manufacturer, has reached a significant milestone with a marketing authorisation from Azerbaijan for the first time for enoxaparin, an anticoagulant that plays a crucial role in addressing blood clot formation in patients suffering from deep vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism.

This achievement is part of the company’s strategy to tap Azerbaijan’s pharmaceutical market, which has an annual volume of $850 million, and thereby expand into West Asia and neighbouring East European countries. Azerbaijan’s pharmaceutical market is import dominated, with India accounting for 4-5 per cent of the total pharmaceutical imports, ranking sixth among the top exporting countries.

Indian exports account for roughly Rs. 500 crore of the $3 billion global enoxaparin market. Having an annual capacity of producing more than five million units of enoxaparin at its robotic line, Venus Remedies is among the largest Indian exporters of this drug.

Enoxaparin, which belongs to the group of medicines known as low molecular weight heparin, prevents existing blood clots from enlarging, facilitates the body's natural clot breakdown processes and prevents the formation of new blood clots.

Saransh Chaudhary, CEO, Venus Medicine Research Centre, commented on this significant achievement, saying, "We are proud to announce the successful marketing authorisation for enoxaparin in Azerbaijan. This regulatory approval highlights our product's bioequivalence to the innovator compound and underscores our commitment towards facilitating global access to essential medications. Enoxaparin has proven to be a crucial drug in managing various medical conditions related to blood clotting, and we are pleased to make it available to patients in Azerbaijan for the first time."

Aditi K Chaudhary, president, international business, Venus Remedies, said the company aims to address critical medical needs and improve patient outcomes as a leading player in global healthcare. “The sixth largest exporter of enoxaparin from India, Venus Remedies is also selling this drug in Venezuela, Oman, Spain, Tanzania, Yemen, Uganda and Philippines, among other countries,” she said.

Having secured more than a dozen marketing authorisations for enoxaparin worldwide, Venus Remedies continues to demonstrate its commitment to advancing healthcare solutions that make a meaningful impact on global health.

 Panchkula-based Venus Remedies Ltd is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!